Logo image of HHS

HARTE-HANKS INC (HHS) Stock Fundamental Analysis

NASDAQ:HHS - Nasdaq - US4161962026 - Common Stock - Currency: USD

3.38  -0.23 (-6.37%)

Fundamental Rating

3

HHS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 97 industry peers in the Media industry. While HHS seems to be doing ok healthwise, there are quite some concerns on its profitability. HHS is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

HHS had negative earnings in the past year.
HHS had a positive operating cash flow in the past year.
In multiple years HHS reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: HHS reported negative operating cash flow in multiple years.
HHS Yearly Net Income VS EBIT VS OCF VS FCFHHS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

HHS has a Return On Assets of -30.34%. This is amonst the worse of the industry: HHS underperforms 84.54% of its industry peers.
HHS has a worse Return On Equity (-142.47%) than 80.41% of its industry peers.
The Return On Invested Capital of HHS (8.86%) is better than 85.57% of its industry peers.
HHS had an Average Return On Invested Capital over the past 3 years of 11.42%. This is above the industry average of 7.56%.
Industry RankSector Rank
ROA -30.34%
ROE -142.47%
ROIC 8.86%
ROA(3y)-0.52%
ROA(5y)1.66%
ROE(3y)13.57%
ROE(5y)N/A
ROIC(3y)11.42%
ROIC(5y)N/A
HHS Yearly ROA, ROE, ROICHHS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

1.3 Margins

Looking at the Operating Margin, with a value of 3.99%, HHS is in line with its industry, outperforming 50.52% of the companies in the same industry.
In the last couple of years the Operating Margin of HHS has declined.
Looking at the Gross Margin, with a value of 18.92%, HHS is doing worse than 76.29% of the companies in the same industry.
In the last couple of years the Gross Margin of HHS has grown nicely.
Industry RankSector Rank
OM 3.99%
PM (TTM) N/A
GM 18.92%
OM growth 3Y-16.84%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.08%
GM growth 5Y15.62%
HHS Yearly Profit, Operating, Gross MarginsHHS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

More info and screens

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), HHS is creating some value.
The number of shares outstanding for HHS has been increased compared to 1 year ago.
HHS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for HHS is higher compared to a year ago.
HHS Yearly Shares OutstandingHHS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
HHS Yearly Total Debt VS Total AssetsHHS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 13.78 indicates that HHS is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 13.78, HHS belongs to the top of the industry, outperforming 93.81% of the companies in the same industry.
A Debt/Equity ratio of 0.03 indicates that HHS is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.03, HHS belongs to the top of the industry, outperforming 83.51% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 13.78
ROIC/WACC0.99
WACC8.99%
HHS Yearly LT Debt VS Equity VS FCFHHS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 1.49 indicates that HHS should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.49, HHS is in line with its industry, outperforming 57.73% of the companies in the same industry.
HHS has a Quick Ratio of 1.49. This is a normal value and indicates that HHS is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.49, HHS is in line with its industry, outperforming 58.76% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.49
Quick Ratio 1.49
HHS Yearly Current Assets VS Current LiabilitesHHS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for HHS have decreased strongly by -2957.21% in the last year.
The Revenue has decreased by -4.47% in the past year.
HHS shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.17% yearly.
EPS 1Y (TTM)-2957.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-125.85%
Revenue 1Y (TTM)-4.47%
Revenue growth 3Y-1.63%
Revenue growth 5Y-3.17%
Sales Q2Q%-8.55%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y131.2%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year4.05%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HHS Yearly Revenue VS EstimatesHHS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M
HHS Yearly EPS VS EstimatesHHS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5 -10 -15

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

HHS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
HHS is valuated cheaply with a Price/Forward Earnings ratio of 3.13.
Based on the Price/Forward Earnings ratio, HHS is valued cheaper than 95.88% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.33, HHS is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 3.13
HHS Price Earnings VS Forward Price EarningsHHS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

97.94% of the companies in the same industry are more expensive than HHS, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1.58
HHS Per share dataHHS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HHS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HARTE-HANKS INC

NASDAQ:HHS (7/15/2025, 8:00:01 PM)

3.38

-0.23 (-6.37%)

Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupMedia & Entertainment
GICS IndustryMedia
Earnings (Last)05-14 2025-05-14
Earnings (Next)08-07 2025-08-07
Inst Owners32.17%
Inst Owner Change0%
Ins Owners38.44%
Ins Owner Change1.92%
Market Cap24.88M
Analysts80
Price Target17.85 (428.11%)
Short Float %0.46%
Short Ratio1.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 3.13
P/S 0.14
P/FCF N/A
P/OCF 13.18
P/B 1.16
P/tB 1.21
EV/EBITDA 1.58
EPS(TTM)-4.2
EYN/A
EPS(NY)1.08
Fwd EY31.97%
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)0.26
OCFY7.59%
SpS24.64
BVpS2.91
TBVpS2.8
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.34%
ROE -142.47%
ROCE 11.21%
ROIC 8.86%
ROICexc 10.29%
ROICexgc 10.45%
OM 3.99%
PM (TTM) N/A
GM 18.92%
FCFM N/A
ROA(3y)-0.52%
ROA(5y)1.66%
ROE(3y)13.57%
ROE(5y)N/A
ROIC(3y)11.42%
ROIC(5y)N/A
ROICexc(3y)13.82%
ROICexc(5y)N/A
ROICexgc(3y)14.26%
ROICexgc(5y)N/A
ROCE(3y)14.46%
ROCE(5y)N/A
ROICexcg growth 3Y-19.31%
ROICexcg growth 5YN/A
ROICexc growth 3Y-19.72%
ROICexc growth 5YN/A
OM growth 3Y-16.84%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.08%
GM growth 5Y15.62%
F-Score6
Asset Turnover1.8
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA 0.05
Cap/Depr 75.53%
Cap/Sales 1.83%
Interest Coverage 250
Cash Conversion 16.22%
Profit Quality N/A
Current Ratio 1.49
Quick Ratio 1.49
Altman-Z 13.78
F-Score6
WACC8.99%
ROIC/WACC0.99
Cap/Depr(3y)122.2%
Cap/Depr(5y)111.4%
Cap/Sales(3y)2.1%
Cap/Sales(5y)1.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2957.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-125.85%
EPS Next Y131.2%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-4.47%
Revenue growth 3Y-1.63%
Revenue growth 5Y-3.17%
Sales Q2Q%-8.55%
Revenue Next Year4.05%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-21.7%
EBIT growth 3Y-18.2%
EBIT growth 5YN/A
EBIT Next Year198.68%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-105.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-93.97%
OCF growth 3YN/A
OCF growth 5YN/A